A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies (NCT05957367)
A Master Protocol for the Multi-Cohort, Phase 1/2 Study of DCC-3116 in Combination With Anticancer Therapies in Participants With Advanced Malignancies
🩺 Plain-English Summary (8th-Grade Level)
This is a Phase 1/2, multicenter, open-label (unless otherwise specified in a combination-specific module) study of inlexisertib in combination with anticancer therapies. Modules within the master protocol are defined according to different combinations of inlexisertib with other anticancer agents.
Who can join: Review the eligibility criteria below.
Location: University of Southern California - Norris Comprehensive Cancer Center — Los Angeles, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (28 Sites)
Showing the first 25 of 28 sites.
- University of Southern California - Norris Comprehensive Cancer Center — Los Angeles, California
- UCLA Department of Medicine-Hematology/Oncology — Los Angeles, California
- Sylvester Comprehensive Cancer Center — Miami, Florida
- University of Massachusetts Worcester — Worcester, Massachusetts
- START Midwest — Grand Rapids, Michigan
- Washington University School of Medicine - Siteman Cancer Center — St Louis, Missouri
- Memorial Sloan Kettering Cancer Center - Main Campus — New York, New York
- Cleveland Clinic Taussig Cancer Center — Cleveland, Ohio
- Oregon Health & Science University — Portland, Oregon
- Fox Chase Cancer Center — Philadelphia, Pennsylvania
- Virginia Cancer Specialist, PC — Fairfax, Virginia
- Aarhus University Hospital — Aarhus,
- Centre Oscar Lambret — Lille,
- Institut Curie, Service d'Oncologie Médicale — Paris,
- Hôpital Européen Georges Pompidou — Paris,
- Universitatsklinikum Franfurt — Frankfurt,
- Universitätsklinikum Eppendorf — Hamburg,
- AOU Careggi - Padiglione 16 - Piano Terra - Ambulatori Oncologici - Ufficio Trial — Florence,
- IRCCS Azienda Ospedaliera Metropolitana — Genova,
- Istituto Europeo di Oncologia — Milan,
- Antonie Van Leeuwenhoek Hospital — Amsterdam,
- Radboudumc — Nijmegen,
- Instituto Português de Oncologia do Porto Francisco Gentil, E.P.E. — Porto,
- ICO Hospitalet — Barcelona,
- Hospital Universitario Ramón y Cajal — Madrid,
📞 Contact the Study Coordinator
Phone: (888) 724-3274
Email: Clinicaltrials@deciphera.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in GIST
- A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib — La Jolla, California
- LRG GIST Patient Registry — Wayne, New Jersey
Explore by condition: All GIST clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.